Adaptive Biotechnologies announced a proposed private offering of $250 million in convertible senior notes due 2031, with an option for an additional $37.5 million. The proceeds will primarily repay the OrbiMed Purchase Agreement, repurchase up to $25 million of common stock to reduce dilution, and support general corporate and MRD business initiatives. The notes will be senior unsecured debt, convertible into cash or stock, and include capped call transactions to limit dilution. This financing aims to enhance the company's financial flexibility and support growth opportunities in its immune medicine platform.
Adaptive Biotechnologies announced it will separate its profitable Minimal Residual Disease (MRD) diagnostics business, which has grown significantly and reached profitability, from its Immune Medicine business, which focuses on AI-driven immune data...
Harvest Investment Services has sold 356,000 shares of Adaptive Biotechnologies, totaling approximately $5.7 million. This significant sale may impact the stock's market perception and price. Investors should watch for any further moves by major shar...
